Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRBP Corbus Pharmaceuticals

Pre-Mkt 05-20 07:22:41 EDT

9.15

-0.80

-8.04%

盘前9.35

+0.20+2.19%

07:00 EDT

High10.04	Low9.09	Vol324.66K
Open9.79	D1 Closing9.95	Amplitude9.55%
Mkt Cap169.53M	Tradable Cap123.83M	Total Shares18.53M
T/O3.07M	T/O Rate2.40%	Tradable Shares13.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRBP","market":"US","secType":"STK","nameCN":"Corbus Pharmaceuticals","latestPrice":9.15,"timestamp":1779220800000,"preClose":9.95,"halted":0,"volume":324663,"hourTrading":{"tag":"盘前","latestPrice":9.35,"preClose":9.15,"latestTime":"07:00 EDT","volume":97,"amount":906.9499999999999,"timestamp":1779274814119,"change":0.2,"changeRate":0.021858,"amplitude":0},"delay":0,"changeRate":-0.08040201005025116,"floatShares":13532800,"shares":18527795,"eps":-5.660431,"marketStatus":"Pre-Mkt","change":-0.8,"latestTime":"05-20 07:22:41 EDT","open":9.79,"high":10.04,"low":9.09,"amount":3071123.3507970003,"amplitude":0.095477,"askPrice":9.5,"askSize":565,"bidPrice":9,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-5.660431,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779283800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.15,"preHourTrading":{"tag":"盘前","latestPrice":9.35,"preClose":9.15,"latestTime":"07:00 EDT","volume":97,"amount":906.9499999999999,"timestamp":1779274814119,"change":0.2,"changeRate":0.021858,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":9.17,"preClose":9.15,"latestTime":"19:55 EDT","volume":1572,"amount":14553.9106,"timestamp":1779234928203,"change":0.02,"changeRate":0.002186,"amplitude":0.010929},"volumeRatio":1.3539121977284476,"impliedVol":0.9609,"impliedVolPercentile":0.476},"requestUrl":"/m/hq/s/CRBP","defaultTab":"news","newsList":[{"id":"2636586782","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2636586782","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636586782?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:19","pubTimestamp":1779225540,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  shed 8.04% to $9.15 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 0.84% to 25,870.71 and Dow Jones Industrial Average  falling 0.65% to 49,363.88.This was the stock's fourth consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 55.50% below its 52-week high of $20.56, which the company achieved on October 20th.The stock underperformed when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  fell 1.48% to $5.99, Fortress Biotech Inc.  rose 2.02% to $2.53, and Viking Therapeutics Inc.  fell 1.01% to $28.40.Trading volume  eclipsed its 50-day average volume of 264,933.Data source: Dow Jones Market Data, FactSet. Data compiled May 19, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636941009","title":"Corbus Pharmaceuticals Holdings Inc. Stock Falls 9.8%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2636941009","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636941009?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:33","pubTimestamp":1779136380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. shed 9.8% to $9.95 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.3% to 49,686.12 and the NASDAQ Composite Index falling 0.5% to 26,090.73.This was the stock's third consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 51.6% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. fell 3.2% to $6.08, Fortress Biotech Inc. rose 2.9% to $2.48, and Viking Therapeutics Inc. fell 5.22% to $28.69.Trading volume totaled 232,426, compared to the 50-day average of 263,554.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635547066","title":"Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2635547066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635547066?lang=en_us&edition=fundamental","pubTime":"2026-05-16 22:36","pubTimestamp":1778942190,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Corbus Pharmaceuticals today and set a price target of $38.00. According to TipR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/corbus-pharmaceuticals-crbp-receives-a-buy-from-lifesci-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/corbus-pharmaceuticals-crbp-receives-a-buy-from-lifesci-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635729097","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2635729097","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635729097?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:20","pubTimestamp":1778793600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  slipped 1.40% to $11.98 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index  rising 0.88% to 26,635.22 and the Dow Jones Industrial Average  rising 0.75% to 50,063.46.The stock's fall snapped a four-day winning streak.Corbus Pharmaceuticals Holdings Inc. closed 41.73% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock underperformed when compared to some of its competitors Thursday, as Vanda Pharmaceuticals Inc.  fell 0.62% to $6.39, Fortress Biotech Inc.  rose 3.14% to $2.30, and Viking Therapeutics Inc.  rose 0.03% to $31.71.Trading volume  remained 47,095 below its 50-day average volume of 264,952.Data source: Dow Jones Market Data, FactSet. Data compiled May 14, 2026.This content was created by MarketWatch, which is operated by Dow J","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635440710","title":"Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635440710","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635440710?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:48","pubTimestamp":1778762920,"startTime":"0","endTime":"0","summary":"An announcement from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On May 13, 2026, Corbus Pharmaceuticals’ board appointed veteran pharma e...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/corbus-pharmaceuticals-adds-independent-director-amid-governance-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/corbus-pharmaceuticals-adds-independent-director-amid-governance-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635128527","title":"Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2635128527","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635128527?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA4SDRXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","BK4539","IPSC","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635373820","title":"Corbus Pharmaceuticals Price Target Maintained With a $45.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2635373820","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635373820?lang=en_us&edition=fundamental","pubTime":"2026-05-13 22:04","pubTimestamp":1778681040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 10:04 ET (14:04 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787487","title":"Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787487","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635787487?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:01","pubTimestamp":1778677307,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings Inc (CRBP) has an average rating of buy and mean price target of $40.78, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic res","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785782","title":"Wedbush Remains a Buy on Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785782?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:39","pubTimestamp":1778675977,"startTime":"0","endTime":"0","summary":"In a report released today, from Wedbush reiterated a Buy rating on Corbus Pharmaceuticals, with a price target of $38.00. In a report released tod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635861437","title":"Corbus Pharma CEO presents at RBC Capital Markets Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2635861437","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635861437?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:05","pubTimestamp":1778670333,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals scheduled to present at RBC Capital Markets Global Healthcare Conference in New York on May 19, 2026.Corporate overview set for 2:05 p.m. EDT, alongside one-on-one investor meetings.CEO Yuval Cohen also slated to present at Jefferies Global Healthcare Conference in New York on June 4, 2026, at 4:55 p.m. EDT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLsmY0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","BK4588","SG9999014039.USD","BK4139","BK4112","IE00BN0W2V16.EUR","NDAQ","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","LU2095319765.USD","IE00B64PRP62.GBP","CRBP","SG9999014021.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786948","title":"Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786948","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786948?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670000,"startTime":"0","endTime":"0","summary":"NORWOOD, Mass., May  13, 2026  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293824/0/en/Corbus-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635422653","title":"Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2635422653","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635422653?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:12","pubTimestamp":1778623921,"startTime":"0","endTime":"0","summary":"Jefferies analyst Maury Raycroft lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $33 from $36 and keeps a Buy rating on the sha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-price-target-lowered-to-33-from-36-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-price-target-lowered-to-33-from-36-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223232","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223232?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:21","pubTimestamp":1778620860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 3.53% to $11.43 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average  rising 0.11% to 49,760.56 and the NASDAQ Composite Index  falling 0.71% to 26,088.20.This was the stock's third consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 44.41% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock outperformed some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  rose 2.39% to $6.42, Fortress Biotech Inc.  rose 0.89% to $2.26, and Viking Therapeutics Inc.  fell 1.26% to $31.32.Trading volume  eclipsed its 50-day average volume of 261,494.Data source: Dow Jones Market Data, FactSet. Data compiled May 12, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635246579","title":"Corbus Pharmaceuticals reports Q1 EPS ($1.23), consensus ($1.22)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635246579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635246579?lang=en_us&edition=fundamental","pubTime":"2026-05-13 00:17","pubTimestamp":1778602625,"startTime":"0","endTime":"0","summary":"“We’ve continued to build strong momentum with CRB-701 and CRB-913, setting the stage for rapidly approaching inflection points for both the oncolo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-reports-q1-eps-1-23-consensus-1-22-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-reports-q1-eps-1-23-consensus-1-22-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634873219","title":"Corbus Pharmaceuticals Q1 EPS $(1.23) Misses $(1.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634873219","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634873219?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:08","pubTimestamp":1778587695,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.22) by 0.82 percent. This is a 11.51 percent increase over losses of $(1.39) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52482205/corbus-pharmaceuticals-q1-eps-1-23-misses-1-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216276","title":"Corbus Q1 FY26 net loss widens to $23 million; operating expenses rise to $24.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216276","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216276?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:02","pubTimestamp":1778587331,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals posted a Q1 net loss of USD 23 million, widening from USD 17 million a year earlier, while loss per share narrowed to USD 1.23 from USD 1.39.Total operating expenses climbed 22.89% to USD 24.3 million, driven by higher clinical development spending.Cash, cash equivalents, and investments totaled USD 138.2 million at March 31, expected to fund operations into 2028.FDA alignment reached on registration path for CRB-701 in second-line head and neck squamous cell carcinoma and cervical cancer; registrational study in 2L HNSCC targeted to start this summer.Enrollment completed in 16-week CANYON-1 Phase 1b obesity study of CRB-913 , with topline data slated for summer 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6JDxdk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634161642","title":"Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634161642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634161642?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587208,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA8FY1VC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633927936","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2633927936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633927936?lang=en_us&edition=fundamental","pubTime":"2026-05-06 05:22","pubTimestamp":1778016120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 1.43% to $10.67 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index  rising 1.03% to 25,326.13 and the Dow Jones Industrial Average  rising 0.73% to 49,298.25.This was the stock's fourth consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 48.10% below its 52-week high of $20.56, which the company reached on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  fell 2.25% to $7.39, Fortress Biotech Inc.  rose 3.36% to $2.46, and Viking Therapeutics Inc.  fell 1.42% to $31.31.Trading volume  remained 15,358 below its 50-day average volume of 250,305.Data source: Dow Jones Market Data, FactSet. Data compiled May 5, 2026.This content was created by MarketWatch, which is operate","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633321910","title":"Corbus hosts ASCO KOL event on updated CRB-701 HNSCC Phase 1/2 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2633321910","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633321910?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:01","pubTimestamp":1777982478,"startTime":"0","endTime":"0","summary":"Corbus scheduled an in-person and virtual KOL event at ASCO 2026 to discuss updated Phase 1/2 CRB-701 monotherapy data in head and neck squamous cell carcinoma.Results will be presented in a poster session during ASCO 2026, with the KOL discussion set for June 1, 2026.Update expected to address how long responses have held up, with analysis across patient subgroups.Company also flagged alignment with FDA on a registration path for CRB-701 in this indication, supporting a potential move toward later-stage development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL7LNNc8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633961468","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2633961468","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633961468?lang=en_us&edition=fundamental","pubTime":"2026-05-05 05:21","pubTimestamp":1777929660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 2.14% to $10.52 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 0.19% to 25,067.80 and Dow Jones Industrial Average  falling 1.13% to 48,941.90.This was the stock's third consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 48.83% below its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its competitors Monday, as Vanda Pharmaceuticals Inc.  rose 8.00% to $7.56, Fortress Biotech Inc.  rose 2.15% to $2.38, and Viking Therapeutics Inc.  rose 5.87% to $31.76.Trading volume  eclipsed its 50-day average volume of 246,695.Data source: Dow Jones Market Data, FactSet. Data compiled May 4, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corbuspharma.com","stockEarnings":[{"period":"1week","weight":-0.1995},{"period":"1month","weight":-0.136},{"period":"3month","weight":0.2348},{"period":"6month","weight":-0.2173},{"period":"1year","weight":0.1791},{"period":"ytd","weight":0.1241}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0691},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.2335},{"period":"ytd","weight":0.076}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.363358},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.048678},{"month":3,"riseRate":0.636364,"avgChangeRate":0.197993},{"month":4,"riseRate":0.545455,"avgChangeRate":0.046477},{"month":5,"riseRate":0.583333,"avgChangeRate":0.06643},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.065346},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.050382},{"month":8,"riseRate":0.636364,"avgChangeRate":0.095672},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.086452},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.124298},{"month":11,"riseRate":0.727273,"avgChangeRate":0.130055},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.132264}],"exchange":"NASDAQ","name":"Corbus Pharmaceuticals","nameEN":"Corbus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corbus Pharmaceuticals,CRBP,Corbus Pharmaceuticals股票,Corbus Pharmaceuticals股票老虎,Corbus Pharmaceuticals股票老虎国际,Corbus Pharmaceuticals行情,Corbus Pharmaceuticals股票行情,Corbus Pharmaceuticals股价,Corbus Pharmaceuticals股市,Corbus Pharmaceuticals股票价格,Corbus Pharmaceuticals股票交易,Corbus Pharmaceuticals股票购买,Corbus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}